Dr. John D. Bisognano

Dr. Hummel is the Director for Heart Failure with Preserved Ejection (HFpEF) program at the Frankel Cardiovascular Center. The HFpEF clinical program incorporates multi-domain assessment and management, with the goals of improving quality of life and long-term outcomes while uncovering and treating the underlying causes of this complex syndrome. The Michigan Medicine HFpEF program also offers access to groundbreaking clinical trials which incorporate interventions ranging from dietary support and medications to implantable cardiac devices for HFpEF. In addition to industry-sponsored trials, Dr. Hummel’s own research has been funded by the NHLBI, NIA, AHRQ, and the VA. This work aims to understand the impact of diet on HFpEF development and progression, and to facilitate healthy eating through technological innovation.As part of the American College of Cardiology’s Geriatric Cardiology leadership council, Dr. Hummel also studies the importance of geriatric domains, such as malnutrition, frailty, and polypharmacy, in heart failure assessment and management. Dr. Hummel is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Pulmonary Edema, Heart Transplant, and Cardiac Ablation. Dr. Hummel is board certified in Cardiovascular Disease and Advanced Heart Failure & Transplant Cardiology. Dr. Hummel is currently accepting new patients.

Todd Koelling joined the University of Michigan faculty in 1997. At present, Dr. Koelling is the Medical Director of Heart Failure and co-directs the Heart Failure and Heart Transplantation Management Program at the University of Michigan. He is a Professor in the Department of Internal Medicine. His research interests include heart failure quality improvement, heart failure management, and risk/prognosis assessment. He has studied targeted patient education interventions in heart failure patients and has directed community hospital quality improvement initiatives in the State of Michigan. He is committed to improving the quality of care provided to patients with advanced heart failure treated at the University of Michigan Health System. Dr. Koelling is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Heart Failure, Cardiomyopathy, Sarcoidosis, Heart Transplant, and Heart Valve Repair. Dr. Koelling is board certified in Advanced Heart Failure & Transplant Cardiology. Dr. Koelling is currently accepting new patients.

Keith Aaronson, MD, PhD, MS, is the Bertram Pitt, MD Collegiate Professor of Cardiovascular Medicine and Professor of Internal Medicine in the Division of Cardiovascular Medicine, University of Michigan Medical School, the Medical Director of the Cardiac Transplant Service and the Center for Circulatory Support and the Co-Director of the Heart Failure and Transplant Management Program for Michigan Medicine. Dr. Aaronson is actively engaged in clinical practice and clinical research in the areas of heart failure, heart transplantation and mechanical circulatory support. His research has focused on improving health, quality of life and economic outcomes in these populations, utilizing methodologies ranging from small to large scale observational analyses, Markov modeling, meta-analyses, and both industry-sponsored and investigator-initiated randomized clinical trials of standard pharmaceutical interventions, alternative medicines, patient education and mechanical circulatory support. Dr. Aaronson has had a particular interest in modeling outcomes in advanced heart failure, heart transplantation and mechanical circulatory support to inform appropriate utilization of health resources. He co-developed the first prospectively validated survival model for patients with advanced heart failure, the Heart Failure Survival Score, which remains in use by heart failure specialists worldwide to help select the most appropriate candidates for heart transplantation and other advanced therapies. He was national Co-PI of the completed HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial, the NHLBI-funded REVIVE-IT trial and the ongoing REVIVAL registry. His present research includes investigations of novel devices for percutaneous circulatory support, cardiac remodeling and cardiorenal syndrome. Dr. Aaronson is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Heart Failure, Pulmonary Edema, Cardiomyopathy, Heart Transplant, and Atherectomy. Dr. Aaronson is board certified in Advanced Heart Failure & Transplant Cardiology and Internal Medicine. Dr. Aaronson is currently accepting new patients.